Anmeldung erfolgt in Kürze...
Details werden geladen...
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at...
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen across all dose cohorts achieved 39% ORR and 7.3-month median PFSIn the 250 mg QD 5:2 intermittent dose cohort, 50% ORR, 9.2-month median DOR, and low frequency of high-grade adverse events was observed, suggesting a potential optimal dose combination SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 - June 2, 2026, in Chicago, Illinois. The poster, titled 'Azenosertib Plus Paclitaxel for Platinum-Resistant Ovarian Cancer: Results From a Phase 1b Study,' will be presented in the Gynecologic Cancer Poster Session (Abstract #5529, Poster Board #195) on June 1, 2026, from 9:00am-12:00pm CDT.
Ähnliche Seiten
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy
https://www.finanznachrichten.de/nachrichten-2026-05/68520145-prokarium-reports-positive-interim-data-from-phase-1-1b-paradigm-1-trial-of-zh9-in-nmibc-patients-demonstrating-excellent-safety-and-encouraging-earl-004.htm
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccR...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/hibercell-to-present-preliminary-results-from-the-phase-1b-trial-of-gcn2-activator-hc-7366-when-combined-with-welireg-belzutifan-for-the-treatment-of-late-line-clear-cell-renal-cell-carcinoma-ccrcc-at-the-upcoming-2026-asco-annual-meeting/2349697Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting |...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/rgenta-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-1ab-clinical-trial-of-rgt-61159-in-patients-with-adenoid-cystic-carcinoma-and-colorectal-cancer-at-the-2026-asco-meeting/2349695Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the ...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/blossomhill-therapeutics-to-present-preliminary-results-from-phase-1-dose-escalationbackfill-cohorts-in-phase-12-solara-trial-of-omni-egfr-inhibitor-bh-30643-in-advanced-egfr-mutant-nsclc-at-the-2026-asco-annual-meeting/2349696